Convergence Scholars

=

November 2, 2020. The MIT Center for Precision Cancer Medicine and the Marble Center for Cancer Nanomedicine are pleased to announce this year's class of Convergence Scholars.

The Convergence Scholars Program (CSP) provides postdoctoral trainees with opportunities to further their experiences and skills beyond the research laboratory. Scholars will learn more about science project development, policy, technology transfer, education and outreach, business and finances, industry, and the clinic.

At the core of CSP are activities to advance the scholars' communication and management skills, as well as to focus on the translational impact of their work. Participant activities and benefits include workshops on management and leadership, deeper engagement with industry, and professional development activities. Supplementing the primary benefit of leadership training and an enhanced perspective in science communication and management, postdoctoral trainees participating in the program will receive a stipend to support additional professional development activities.

 

2020 CPCM Scholars (left to right): Dan Goulet, Jeff Davis, Jasmin Kruell, Ingred Goretti Rica, Tigist Tamir, Ye Zhang

  • Jeffrey Davis, Vander Heiden Lab: Jeff studies the metabolic programs that determine cell fate acquisition and differentiation potential in development and cancer.
  • Daniel Goulet, Hemann Lab: Using a mouse model of B-cell acute lymphoblastic leukemia, Daniel’s work aims at identifying the tumor cell intrinsic and extrinsic factors that contribute to drug resistance.
  • Jasmin Kruell, Koehler Lab: Jasmin’s research is focused on targeting the transcription factor Myb using small molecules in acute myeloid leukemia.
  • Ingred Goretti Rica, Yaffe Lab: Ingred is studying the role of a specific population of neutrophils with immunosuppressive properties in the tumor microenvironment and trauma.
  • Tigist Tamir, White Lab: In her work, Tigist uses a multi-omics approach to understand functional modifications on proteins in cancer resistance.
  • Ye Zhang, Manalis Lab: Ye is developing and utilizing microfluidic platforms to measure biophysical properties of tumor cells.